All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results FACCT Trial, 2021 0.69 [0.28; 1.68]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
RECOVERY, 2020 1.09 [0.97; 1.23]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
1.07 [0.95 ; 1.21 ] FACCT Trial, 2021, HYDRA (Hernandez-Cardenas), 2021, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020 4 6% 7,037 moderate not evaluable deathsdetailed results Abd-Elsalam, 2020 1.21 [0.36; 4.12]
Chen, 2020 0.56 [0.01; 30.20]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52]
FACCT Trial, 2021 0.96 [0.44; 2.08]
Galan, 2021 0.94 [0.51; 1.73]
Gonzalez (HCQ), 2020 0.33 [0.06; 1.78]
HAHPS, 2020 7.00 [0.80; 60.90]
HYCOVID, 2020 0.54 [0.21; 1.40]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
NO COVID-19 (Lyngbakken), 2020 0.96 [0.06; 15.78]
NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20]
ORCHID, 2020 1.07 [0.54; 2.11]
RECOVERY, 2020 1.09 [0.97; 1.23]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
TEACH, 2020 1.07 [0.34; 3.37]
1.07 [0.97 ; 1.19 ] Abd-Elsalam, 2020, Chen, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, FACCT Trial, 2021, Galan, 2021, Gonzalez (HCQ), 2020, HAHPS, 2020, HYCOVID, 2020, HYDRA (Hernandez-Cardenas), 2021, NO COVID-19 (Lyngbakken), 2020, NOR-Solidarity (hydroxychloroquine), 2021, ORCHID, 2020, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020, TEACH, 2020 15 0% 8,938 moderate low deaths (time to event analysis only)detailed results Galan, 2021 0.94 [0.51; 1.73]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20]
RECOVERY, 2020 1.09 [0.97; 1.23]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
1.08 [0.97 ; 1.20 ] Galan, 2021, HYDRA (Hernandez-Cardenas), 2021, NOR-Solidarity (hydroxychloroquine), 2021, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020 5 0% 7,063 moderate not evaluable clinical deteriorationdetailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12]
HAHPS, 2020 1.07 [0.63; 1.82]
TEACH, 2020 1.80 [0.62; 5.21]
1.20 [0.83 ; 1.72 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, HAHPS, 2020, TEACH, 2020 3 0% 460 moderate not evaluable clinical improvementdetailed results ORCHID, 2020 1.02 [0.73; 1.42]
1.02 [0.73 ; 1.42 ] ORCHID, 2020 1 0% 479 NA not evaluable clinical improvement (14-day)detailed results Chen, 2020 0.56 [0.13; 2.48]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44]
ORCHID, 2020 1.02 [0.73; 1.42]
0.95 [0.71 ; 1.25 ] Chen, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, ORCHID, 2020 3 0% 960 low not evaluable clinical improvement (28-day)detailed results ORCHID, 2020 0.97 [0.69; 1.37]
0.97 [0.69 ; 1.37 ] ORCHID, 2020 1 0% 479 NA not evaluable clinical improvement (7-day)detailed results ORCHID, 2020 1.16 [0.84; 1.61]
1.16 [0.84 ; 1.61 ] ORCHID, 2020 1 0% 479 NA not evaluable clinical improvement (time to event analysis only)detailed results FACCT Trial, 2021 0.85 [0.62; 1.16]
HYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48]
ORCHID, 2020 0.97 [0.69; 1.36]
0.94 [0.78 ; 1.14 ] FACCT Trial, 2021, HYDRA (Hernandez-Cardenas), 2021, ORCHID, 2020 3 0% 947 moderate not evaluable death or ventilationdetailed results Gonzalez (HCQ), 2020 0.69 [0.22; 2.21]
HYCOVID, 2020 1.12 [0.45; 2.79]
ORCHID, 2020 1.13 [0.60; 2.13]
RECOVERY, 2020 1.14 [1.03; 1.27]
SOLIDARITY (WHO study) HCQ, 2020 1.11 [0.87; 1.42]
1.13 [1.03 ; 1.24 ] Gonzalez (HCQ), 2020, HYCOVID, 2020, ORCHID, 2020, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020 5 0% 6,570 moderate not evaluable hospital dischargedetailed results FACCT Trial, 2021 0.88 [0.64; 1.21]
Gonzalez (HCQ), 2020 1.38 [0.46; 4.16]
HAHPS, 2020 0.91 [0.54; 1.54]
HYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42]
0.94 [0.77 ; 1.17 ] FACCT Trial, 2021, Gonzalez (HCQ), 2020, HAHPS, 2020, HYDRA (Hernandez-Cardenas), 2021 4 0% 623 moderate not evaluable mechanical ventilationdetailed results Galan, 2021 0.14 [0.03; 0.71]
0.14 [0.03 ; 0.71 ] Galan, 2021 1 0% 168 NA not evaluable viral clearance by day 14detailed results Chen, 2020 1.42 [0.26; 7.76]
1.42 [0.26 ; 7.76 ] Chen, 2020 1 0% 33 NA not evaluable ICU admissiondetailed results Abd-Elsalam, 2020 0.83 [0.35; 1.95]
FACCT Trial, 2021 1.42 [0.79; 2.55]
Galan, 2021 1.42 [0.68; 2.99]
1.26 [0.84 ; 1.89 ] Abd-Elsalam, 2020, FACCT Trial, 2021, Galan, 2021 3 0% 616 moderate not evaluable off oxygenationdetailed results HYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51]
0.98 [0.64 ; 1.51 ] HYDRA (Hernandez-Cardenas), 2021 1 0% 214 NA not evaluable cardiac arrestdetailed results SOLIDARITY (WHO study) HCQ, 2020 1.92 [0.35; 10.49]
1.92 [0.35 ; 10.49 ] SOLIDARITY (WHO study) HCQ, 2020 1 0% 1,853 NA not evaluable serious adverse eventsdetailed results ORCHID, 2020 1.26 [0.56; 2.84]
1.26 [0.56 ; 2.84 ] ORCHID, 2020 1 0% 479 NA not evaluable adverse eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65]
ORCHID, 2020 1.42 [0.87; 2.34]
RECOVERY, 2020 1.36 [0.98; 1.90]
TEACH, 2020 1.16 [0.55; 2.42]
1.32 [1.03 ; 1.70 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, ORCHID, 2020, RECOVERY, 2020, TEACH, 2020 4 0% 5,655 moderate not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-26 19:44 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290